Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 23, 2021updated 01 Nov 2021 7:15am

FDA approves Agilent’s assay as companion diagnostic for Libtayo

The US Food and Drug Administration (FDA) has approved Agilent Technologies PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic.

The US Food and Drug Administration (FDA) has approved Agilent Technologies PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic.

Currently, the assay can be used in detecting NSCLC patients with tumour PD-L1 expression of Tumor Proportion Score (TPS) greater than or equal to 50% for treatment with Libtayo (cemiplimab-rwlc).

PD-L1 expression is a biomarker for anti-PD-1 therapy response in NSCLC.

The latest expanded indication will help pathologists to detect patients with advanced NSCLC who could be eligible for Libtayo treatment.

Currently, PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic for this purpose.

Agilent Diagnostics and Genomics Group president Sam Raha said: “Anti-PD-1 therapies, including Libtayo, continue to broaden the potential for the treatment of patients across different cancer types.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“With the FDA approval of PD-L1 IHC 22C3 pharmDx as a companion diagnostic for treatment with Libtayo monotherapy in advanced NSCLC, Agilent further strengthens its ability to elevate pathologist confidence in reporting results to oncologists and bolsters our role as a global pioneer in developing companion diagnostics for targeted treatments.”

Regeneron and Sanofi developed Libtayo and collaborated with Agilent for using the assay in assessing PD-L1 expression in patients in the EMPOWER-Lung 1 clinical trial.

PD-1 immunotherapies such as Libtayo provide treatment options to advanced NSCLC patients. For those with stage IVA–IVB disease, the 60-month overall survival rate is 0%-10%.

A fully human monoclonal antibody, Libtayo is directed at the immune checkpoint receptor PD-1 on T-cells. It binds to PD-1 to potentially inhibit cancer cells from using the PD-1 pathway for suppressing T-cell activation.

Last week, Agilent launched a new immunoassay kit for the qualitative detection of SARS-CoV-2 immunoglobulin G (IgG) antibodies in human serum or plasma.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU